Lynn R Webster1, John F Peppin2, Frederick T Murphy3, Biao Lu4, Jeffrey K Tobias4, Geertrui F Vanhove4. 1. Lifetree Clinical Research and Pain Clinic, Salt Lake City, UT, USA. Electronic address: lynnw@lifetreeresearch.com. 2. The Pain Treatment Center of the Bluegrass, Lexington, KY, USA. 3. Altoona Center for Clinical Research, Duncansville, PA, USA. 4. NeurogesX, Inc., San Mateo, CA, USA.
Abstract
AIMS: To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain. METHODS: This open-label, uncontrolled, 12-week study enrolled 25 patients with postherpetic neuralgia (PHN), one with HIV-distal sensory polyneuropathy, and 91 with painful diabetic neuropathy (PDN). Patients received pre-treatment with one of three 4% lidocaine topical anesthetics (L.M.X.4¹, Topicaine Gel², or Betacaine Enhanced Gel 4³) followed by a single 60- or 90-min NGX-4010 application. The primary efficacy variable was the percentage change in Numeric Pain Rating Scale scores from baseline to Weeks 2-12. Adverse events (AEs), laboratory parameters, vital signs, neurosensory examinations, dermal assessments, treatment-related pain scores, and medication use for treatment-related pain were collected. RESULTS: PDN and PHN patients achieved a 31% and 28% mean pain decrease from baseline during Weeks 2-12, respectively, and 47% and 44%, respectively, were responders (≥30% pain decrease). Mild or moderate treatment-site-related burning and pain were the most common AEs and there was no evidence of impaired neurosensory function. CONCLUSIONS: NGX-4010 in conjunction with any of the three topical anesthetics tested was generally safe and well tolerated and reduced pain over a 12-week period in patients with PDN and PHN.
AIMS: To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain. METHODS: This open-label, uncontrolled, 12-week study enrolled 25 patients with postherpetic neuralgia (PHN), one with HIV-distal sensory polyneuropathy, and 91 with painful diabetic neuropathy (PDN). Patients received pre-treatment with one of three 4% lidocaine topical anesthetics (L.M.X.4¹, Topicaine Gel², or Betacaine Enhanced Gel 4³) followed by a single 60- or 90-min NGX-4010 application. The primary efficacy variable was the percentage change in Numeric Pain Rating Scale scores from baseline to Weeks 2-12. Adverse events (AEs), laboratory parameters, vital signs, neurosensory examinations, dermal assessments, treatment-related pain scores, and medication use for treatment-related pain were collected. RESULTS: PDN and PHN patients achieved a 31% and 28% mean pain decrease from baseline during Weeks 2-12, respectively, and 47% and 44%, respectively, were responders (≥30% pain decrease). Mild or moderate treatment-site-related burning and pain were the most common AEs and there was no evidence of impaired neurosensory function. CONCLUSIONS:NGX-4010 in conjunction with any of the three topical anesthetics tested was generally safe and well tolerated and reduced pain over a 12-week period in patients with PDN and PHN.
Authors: Evan E Lebovitz; Jason M Keller; Hal Kominsky; Krisztian Kaszas; Dragan Maric; Michael J Iadarola Journal: Mol Pain Date: 2012-09-21 Impact factor: 3.395
Authors: Christian Martini; Ashraf Yassen; Erik Olofsen; Paul Passier; Malcom Stoker; Albert Dahan Journal: J Pain Res Date: 2012-03-15 Impact factor: 3.133
Authors: Nadia Hussain; Amira S A Said; Farideh A Javaid; Amal Hussain Ibrahim Al Haddad; Mudassir Anwar; Zainab Khan; Abdallah Abu-Mellal Journal: J Diabetes Metab Disord Date: 2021-01-19